PhillyPharma Archive: May, 2013

India's Sun Pharmaceuticals weighs a Swedish acquisition, says former Philly drug company helps sales

Comment icon 0 Comments
Sun Pharmaceutical Industries Ltd., one of India's largest drug makers, said its newly-acquired URL Pharma of Philadelphia helped Sun increase... Read more

New Endo Health Solutions CEO's deputies are departing

Comment icon 0 Comments
PhillyPharma is now available on Inquirer.com. The promo code for signing in is B17B and we'd love to have you sign up. Thanks. Read more

AstraZeneca to buy Princeton-based Omthera Pharmaceuticals for $443 million

Comment icon 0 Comments
AstraZeneca said Tuesday morning it agreed to pay as much as $443 million for Princeton-based Omthera Pharmaceuticals, which is close to being... Read more

Will P&G leadership change impact joint venture with Teva Pharmaceuticals?

Comment icon 0 Comments
The two chief executive officers who engineered the joint venture between Teva Pharmaceuticals and Procter & Gamble are now gone, only... Read more

A good drug in case of......nuclear attack?

Comment icon 0 Comments
Many taxpayers expect the government to plan for every contingency, so perhaps it makes sense to have the Biomedical Advanced Research and... Read more

Actavis CEO: Ireland great for paying less tax, but "everybody loves New Jersey too much" to leave

Comment icon 0 Comments
Apple chief executive Tim Cook spent two hours before a Senate committee Tuesday defending how the computer device maker uses subsidiaries... Read more

Philly guy Gary Gibbons says that just like Big Pharma, NIH needs signs of success sooner

Comment icon 0 Comments
You think you got money problems? Get in line. Gary Gibbons graduated from, and worked at, very fancy schools and medical facilities, but... Read more

Sen. Bob Casey on NIH funding and the problem of balance in health-care spending

Comment icon 0 Comments
Pennsylvania Sen. Bob Casey says he spends a lot of time pushing for funding of the National Institutes of Health because it translates into... Read more